Cytodyn Inc Discusses New HIV Drug and Plans for Commercialization, Addressing $2 Billion Market Call Transcript
Nader, thanks for being with us today.
Thank you for having me, Dave.
Questions & Answers
CytoDyn is developing innovative treatments for multiple therapeutic indications. I want to start with an overview of your development pipeline?
Yes, thank you for that. The combination therapy in HIV, monotherapy in HIV, prevention in HIV, and we have cancer indication, very exciting to us is triple negative breast cancer, colon cancer. And hopefully, now we're going to have a basket trial, which will allow us to enroll 22 different solid tumor indication for cancer. And we also have GvHD, graft versus host disease, and NASH, and also we have a trial for colon cancer.
Let's talk about your Phase 3 trial that you actually
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
